Skip to main content
SpringerLink
Log in

Blood and Bone Marrow Transplantation for Patients with Hodgkin’s and Non-Hodgkin’s Lymphoma

  • Chapter
Hodgkin’s and Non-Hodgkin’s Lymphoma

Part of the book series: Cancer Treatment and Research ((CTAR,volume 131))

Abstract

Most lymphomas are initially sensitive to chemotherapy and radiation. Unfortunately, many patients will relapse with their disease. Dose escalation of chemotherapy is often limited by hematopoetic toxicity. The realization that a significantly higher dose of chemotherapy or chemoradiotherapy could be delivered to a patient by reconstituting their marrow with hematopoetic stem cells paved the way to autologous blood or marrow transplantation (ABMT) for patients with lymphoma. Initial studies were performed in refractory patients. These studies demonstrated the feasibility of this approach and ushered in more definitive trials in patients with homogenous histologies.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

9. References

  1. Gulati SC, Shank B, Black P, et al: Autologous bone marrow transplantation for patients with poor-prognosis lymphoma. J Clin Oncol 6:1303–13, 1988

    PubMed  CAS  Google Scholar 

  2. Stiff PJ, Dahlberg S, Forrnan SJ, et al: Autologous bone marrow transplantation for patients with relapsed or refractory diffuse aggressive non-Hodgkin’s lymphoma: value of augmented preparative regimens-a Southwest Oncology Group trial. J Clin Oncol 16:48–55, 1998

    PubMed  CAS  Google Scholar 

  3. Bosly A, Coiffier B, Gisselbrecht C, et al: Bone marrow transplantation prolongs survival after relapse in aggressive-lymphoma patients treated with the LNH-84 regimen. J Clin Oncol 10:1615–23, 1992

    PubMed  CAS  Google Scholar 

  4. Philip T, Armitage JO, Spitzer G, et al: High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin’s lymphoma. N Engl J Med 316:1493–8, 1987

    Article  PubMed  CAS  Google Scholar 

  5. Petersen FB, Appelbaum FR, Hill R, et al: Autologous marrow transplantation for malignant lymphoma: a report of 101 cases from Seattle. J Clin Oncol 8:638–47, 1990

    PubMed  CAS  Google Scholar 

  6. Vose JM, Anderson JR, Kessinger A, et al: High-dose chemotherapy and autologous hematopoietic stem-cell transplantation for aggressive non-Hodgkin’s lymphoma. J Clin Oncol 11:1846–51, 1993

    PubMed  CAS  Google Scholar 

  7. Mills W, Chopra R, McMillan A, et al: BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin’s lymphoma. J Clin Oncol 13:588–95, 1995

    PubMed  CAS  Google Scholar 

  8. Stockerl-Goldstein KE, Horning SJ, Negrin RS, et al: Influence of preparatory regimen and source of hematopoietic cells on outcome of autotransplantation for non-Hodgkin’s lymphoma. Biol Blood Marrow Transplant 2:76–85, 1996

    PubMed  CAS  Google Scholar 

  9. Caballero MD, Rubio V, Rifon J, et al: BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors. Bone Marrow Transplant 20:451–8, 1997

    Article  PubMed  CAS  Google Scholar 

  10. Rapoport AP, Lifton R, Constine LS, et al: Autotransplantation for relapsed or refractory non-Hodgkin’s lymphoma (NHL): long-term follow-up and analysis of prognostic factors. Bone Marrow Transplant 19:883–90, 1997

    Article  PubMed  CAS  Google Scholar 

  11. Popat U, Przepiork D, Champlin R, et al: High-dose chemotherapy for relapsed and refractory diffuse large B-cell lymphoma: mediastinal localization predicts for a favorable outcome. J Clin Oncol 16:63–9, 1998

    PubMed  CAS  Google Scholar 

  12. Philip T, Guglielmi C, Hagenbeek A, et al: Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma [see comments]. N.Engl.J.Med. 333:1540–1545, 1995

    Article  PubMed  CAS  Google Scholar 

  13. Bierman PJ, Sweetenham JW, Loberiza FR, Jr., et al: Syngeneic hematopoietic stem-cell transplantation for non-Hodgkin’s lymphoma: a comparison with allogeneic and autologous transplantation-The Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation. J Clin Oncol 21:3744–53, 2003

    Article  PubMed  Google Scholar 

  14. Schwonzen M, Pohl C, Steinmetz T, et al: Immunophenotyping of low-grade B-cell lymphoma in blood and bone marrow: poor correlation between immunophenotype and cytological/histological classification. Br J Haematol 83:232–9, 1993

    PubMed  CAS  Google Scholar 

  15. Baidas SM, Cheson BD, Kauh J, et al: Mantle cell lymphoma: clinicopathologic features and treatments. Oncology (Huntingt) 17:879–91, 896; discussion 896–8, 2003

    Google Scholar 

  16. Zucca E, Roggero E, Pinotti G, et al: Patterns of survival in mantle cell lymphoma. Ann Oncol 6:257–62, 1995

    PubMed  CAS  Google Scholar 

  17. Hiddemann W, Dreyling M, Preundschuh M, et al: Myeloablative radiochemotherapy followed by autologous blood stem cell transplantation leads to a significant prolongation of the event-free survival in patients with mantle cell lymphoma (MCL) — results of a prospective randomized European Intergroup study [abstract]. Blood:abstract 3572, 2001

    Google Scholar 

  18. Freedman AS, Neuberg D, Gribben JG, et al: High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: no evidence for long-term remission. J Clin Oncol 16:13–8, 1998

    PubMed  CAS  Google Scholar 

  19. Sweetenham JW: Stem cell transplantation for mantle cell lymphoma: should it ever be used outside clinical trials? Bone Marrow Transplant 28:813–20, 2001

    Article  PubMed  CAS  Google Scholar 

  20. Ketterer N, Salles G, Espinouse D, et al: Intensive therapy with peripheral stem cell transplantation in 16 patients with mantle cell lymphoma. Ann Oncol 8:701–4, 1997

    Article  PubMed  CAS  Google Scholar 

  21. Kasamon YL, Jones RJ, Diehl LF, et al: Outcomes of autologous and allogeneic blood or marrow transplantation for mantle cell lymphoma. Biol Blood Marrow Transplant 11:39–46, 2005

    Article  PubMed  Google Scholar 

  22. Yuen AR, Rosenberg SA, Hoppe RT, et al: Comparison between conventional salvage therapy and high-dose therapy with autografting for recurrent or refractory Hodgkin’s disease. Blood 89:814–22, 1997

    PubMed  CAS  Google Scholar 

  23. Linch DC, Winfield D, Goldstone AH, et al: Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin’s disease: results of a BNLI randomised trial. Lancet 341:1051–4, 1993

    Article  PubMed  CAS  Google Scholar 

  24. Sureda A, Arranz R, Iriondo A, et al: Autologous stem-cell transplantation for Hodgkin’s disease: results and prognostic factors in 494 patients from the Grupo Espanol de Linfomas/Transplante Autologo de Medula Osea Spanish Cooperative Group. J Clin Oncol 19:1395–404, 2001

    PubMed  CAS  Google Scholar 

  25. Akpek G, Ambinder RF, Piantadosi S, et al: Long-term results of blood and marrow transplantation for Hodgkin’s lymphoma. J Clin Oncol 19:4314–21, 2001

    PubMed  CAS  Google Scholar 

  26. Lazarus HM, Rowlings PA, Zhang MJ, et al: Autotransplants for Hodgkin’s disease in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol 17:534–45, 1999

    PubMed  CAS  Google Scholar 

  27. Sweetenham JW, Carella AM, Taghipour G, et al: High-dose therapy and autologous stem-cell transplantation for adult patients with Hodgkin’s disease who do not enter remission after induction chemotherapy: results in 175 patients reported to the European Group for Blood and Marrow Transplantation. Lymphoma Working Party. J Clin Oncol 17:3101–9, 1999

    PubMed  CAS  Google Scholar 

  28. Horning SJ, Chao NJ, Negrin RS, et al: High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin’s disease: analysis of the Stanford University results and prognostic indices. Blood 89:801–13, 1997

    PubMed  CAS  Google Scholar 

  29. Sweetenham JW, Taghipour G, Milligan D, et al: High-dose therapy and autologous stem cell rescue for patients with Hodgkin’s disease in first relapse after chemotherapy: results from the EBMT. Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 20:745–52, 1997

    Article  PubMed  CAS  Google Scholar 

  30. Brice P, Bouabdallah R, Moreau P, et al: Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin’s disease: analysis of 280 patients from the French registry. Societe Francaise de Greffe de Moelle. Bone Marrow Transplant 20:21–6, 1997

    Article  PubMed  CAS  Google Scholar 

  31. Lancet JE, Rapoport AP, Brasacchio R, et al: Autotransplantation for relapsed or refractory Hodgkin’s disease: long-term follow-up and analysis of prognostic factors. Bone Marrow Transplant 22:265–71, 1998

    Article  PubMed  CAS  Google Scholar 

  32. Arranz R, Tomas JF, Gil-Fernandez JJ, et al: Autologous stem cell transplantation (ASCT) for poor prognostic Hodgkin’s disease (HD): comparative results with two CBV regimens and importance of disease status at transplant. Bone Marrow Transplant 21:779–86, 1998

    Article  PubMed  CAS  Google Scholar 

  33. Andre M, Henry-Amar M, Blaise D, et al: Treatment-related deaths and second cancer risk after autologous stem-cell transplantation for Hodgkin’s disease. Blood 92:1933–40, 1998

    PubMed  CAS  Google Scholar 

  34. Bachier CR, Giles RE, Ellerson D, et al: Hematopoietic retroviral gene marking in patients with follicular non-Hodgkin’s lymphoma. Leuk.Lymphoma. 32:279–288, 1999

    PubMed  CAS  Google Scholar 

  35. Press OW, Eary JF, Appelbaum FR, et al: Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support [see comments]. N.Engl.J.Med. 329:1219–1224, 1993

    Article  PubMed  CAS  Google Scholar 

  36. Press OW, Eary JF, Appelbaum FR, et al: Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet 346:336–340, 1995

    Article  PubMed  CAS  Google Scholar 

  37. Liu SY, Eary JF, Petersdorf SH, et al: Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue. J.Clin.Oncol. 16:3270–3278, 1998

    PubMed  CAS  Google Scholar 

  38. Press OW, Eary JF, Gooley T, et al: A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas [In Process Citation]. Blood 96:2934–2942, 2000

    PubMed  CAS  Google Scholar 

  39. Gribben JG, Freedman AS, Neuberg D, et al: Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma [see comments]. N.Engl.J.Med. 325:1525–1533, 1991

    Article  PubMed  CAS  Google Scholar 

  40. Horwitz SM, Negrin RS, Blume KG, et al: Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma. Blood 103:777–83, 2004

    Article  PubMed  CAS  Google Scholar 

  41. Flinn IW, O’Donnell PV, Goodrich A, et al: Immunotherapy with rituximab during peripheral blood stem cell transplantation for non-Hodgkin’s lymphoma. Biol Blood Marrow Transplant 6:628–32, 2000

    Article  PubMed  CAS  Google Scholar 

  42. Magni M, Di Nicola M, Devizzi L, et al: Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion [In Process Citation]. Blood 96:864–869, 2000

    PubMed  CAS  Google Scholar 

  43. Flohr T, Hess G, Kolbe K, et al: Rituximab in vivo purging is safe and effective in combination with CD34-positive selected autologous stem cell transplantation for salvage therapy in B-NHL. Bone Marrow Transplant 29:769–75, 2002

    Article  PubMed  CAS  Google Scholar 

  44. Goldberg SL, Pecora AL, Alter RS, et al: Unusual viral infections (progressive multifocal leukoencephalopathy and cytomegalovirus disease) after high-dose chemotherapy with autologous blood stem cell rescue and peritransplantation rituximab. Blood 99:1486–8, 2002

    Article  PubMed  CAS  Google Scholar 

  45. Thomas ED, Buckner CD, Rudolph RH, et al: Allogeneic marrow grafting for hematologic malignancy using HL-A matched donor-recipient sibling pairs. Blood 38:267–87, 1971

    PubMed  CAS  Google Scholar 

  46. Weiden PL, Flournoy N, Thomas ED, et al: Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med 300:1068–73, 1979

    Article  PubMed  CAS  Google Scholar 

  47. Jones RJ, Ambinder RF, Piantadosi S, et al: Evidence of graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation. Blood 3:649–653, 1991

    Google Scholar 

  48. van Besien KW, de Lima M, Giralt SA, et al: Management of lymphoma recurrence after allogeneic transplantation: the relevance of graft-versus-lymphoma effect. Bone Marrow Transplant 19:977–82, 1997

    Article  PubMed  Google Scholar 

  49. Slavin S, Morecki S, Weiss L, et al: Donor lymphocyte infusion: the use of alloreactive and tumor-reactive lymphocytes for immunotherapy of malignant and nonmalignant diseases in conjunction with allogeneic stem cell transplantation. J Hematother Stem Cell Res 11:265–76, 2002

    Article  PubMed  Google Scholar 

  50. Mandigers CM, Meijerink JP, Raemaekers JM, et al: Graft-versus-lymphoma effect of donor leucocyte infusion shown by real-time quantitative PCR analysis of t(14;18) [letter]. Lancet 352:1522–1523, 1998

    Article  PubMed  CAS  Google Scholar 

  51. Slavin S, Naparstek E, Nagler A, et al: Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes. Exp Hematol 23:1553–62, 1995

    PubMed  CAS  Google Scholar 

  52. Collins RH, Jr., Shpilberg O, Drobyski WR, et al: Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 15:433–44, 1997

    PubMed  Google Scholar 

  53. Horning SJ, Rosenberg SA: The natural history of initially untreated low-grade non-hodgkin’s lymphoma. N Engl J Med 311:1471–1475, 1984

    Article  PubMed  CAS  Google Scholar 

  54. Johnson PW, Rohatiner AZ, Whelan JS, et al: Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center. J Clin Oncol 13:140–7, 1995

    PubMed  CAS  Google Scholar 

  55. Weisdorf DJ, Andersen JW, Glick JH, et al: Survival after relapse of low-grade non-Hodgkin’s lymphoma: implications for marrow transplantation. J Clin Oncol 10:942–7, 1992

    PubMed  CAS  Google Scholar 

  56. Van Besien K, Loberiza FR, Bajorunaite R, et al: Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood, 2003

    Google Scholar 

  57. Verdonck LF: Allogeneic versus autologous bone marrow transplantation for refractory and recurrent low-grade non-Hodgkin’s lymphoma: updated results of the Utrecht experience. Leuk Lymphoma 34:129–36, 1999

    PubMed  CAS  Google Scholar 

  58. van Besien K, Champlin IK, McCarthy P: Allogeneic transplantation for low-grade lymphoma: long-term follow-up. J Clin Oncol 18:702–3, 2000

    PubMed  Google Scholar 

  59. van Besien KW, Khouri IF, Giralt SA, et al: Allogeneic bone marrow transplantation for refractory and recurrent low-grade lymphoma: the case for aggressive management. Journal of Clinical Oncology 13:1096–1102, 1995

    PubMed  Google Scholar 

  60. Mandigers CM, Raemaekers JM, Schattenberg AV, et al: Allogeneic bone marrow transplantation with T-cell-depleted marrow grafts for patients with poor-risk relapsed low-grade non-Hodgkin’s lymphoma. Br J Haematol 100:198–206, 1998

    Article  PubMed  CAS  Google Scholar 

  61. Toze CL, Shepherd JD, Connors JM, et al: Allogeneic bone marrow transplantation for low-grade lymphoma and chronic lymphocytic leukemia. Bone Marrow Transplant. 25:605–612, 2000

    Article  PubMed  CAS  Google Scholar 

  62. Stein RS, Greer JP, Goodman S, et al: High-dose therapy with autologous or allogeneic transplantation as salvage therapy for small cleaved cell lymphoma of follicular center cell origin. Bone Marrow Transplant. 23:227–233, 1999

    Article  PubMed  CAS  Google Scholar 

  63. Juckett M, Rowlings P, Hessner M, et al: T cell-depleted allogeneic bone marrow transplantation for high-risk non-Hodgkin’s lymphoma: clinical and molecular follow-up. Bone Marrow Transplant. 21:893–899, 1998

    Article  PubMed  CAS  Google Scholar 

  64. van Besien K, Sobocinski KA, Rowlings PA, et al: Allogeneic bone marrow transplantation for low-grade lymphoma. Blood 92:1832–1836, 1998

    PubMed  Google Scholar 

  65. Peniket AJ, Ruiz de Elvira MC, Taghipour G, et al: An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. Bone Marrow Transplant 31:667–78, 2003

    Article  PubMed  CAS  Google Scholar 

  66. Forrest DL, Thompson K, Nevill TJ, et al: Allogeneic hematopoietic stem cell transplantation for progressive follicular lymphoma. Bone Marrow Transplant 29:973–8, 2002

    Article  PubMed  CAS  Google Scholar 

  67. Berdeja JG, Jones RJ, Zahurak ML, et al: Allogeneic bone marrow transplantation in patients with sensitive low-grade lymphoma or mantle cell lymphoma. Biol.Blood Marrow Transplant. 2001.:561–567, 2001

    Article  Google Scholar 

  68. Khouri IF, Keating MJ, Saliba RM, et al: Long-term follow-up of patients with CLL treated with allogeneic hematopoietic transplantation. Cytotherapy 4:217–21, 2002

    Article  PubMed  CAS  Google Scholar 

  69. Michallet M, Archimbaud E, Bandini G, et al: HLA-identical sibling bone marrow transplantation in younger patients with chronic lymphocytic leukemia. European Group for Blood and Marrow Transplantation and the International Bone Marrow Transplant Registry. Ann Intern Med 96:311–315, 1996

    Google Scholar 

  70. Pavletic ZS, Arrowsmith ER, Bierman PJ, et al: Outcome of allogeneic stem cell transplantation for B cell chronic lymphocytic leukemia. Bone Marrow Transplant. 25:717–722, 2000

    Article  PubMed  CAS  Google Scholar 

  71. Prince HM, Imrie K, Crump M, et al: The role of intensive therapy and autologous blood and marrow transplantation for chemotherapy-sensitive relapsed and primary refractory non-Hodgkin’s lymphoma: identification of major prognostic groups. Br J Haematol 92:880–9, 1996

    Article  PubMed  CAS  Google Scholar 

  72. Dhedin N, Giraudier S, Gaulard P, et al: Allogeneic bone marrow transplantation in aggressive non-Hodgkin’s lymphoma (excluding Burkitt and lymphoblastic lymphoma): a series of 73 patients from the SFGM database. Societ Francaise de Greffe de Moelle. Br J Haematol 107:154–61, 1999

    Article  PubMed  CAS  Google Scholar 

  73. van Besien KW, Mehra RC, Giralt SA, et al: Allogeneic bone marrow transplantation for poor-prognosis lymphoma: response, toxicity and survival depend on disease histology. American Journal of Medicine 100:299–307, 1996

    Article  PubMed  Google Scholar 

  74. Dann EJ, Daugherty CK, Larson RA: Allogeneic bone marrow transplantation for relapsed and refractory Hodgkin’s disease and non-Hodgkin’s lymphoma. Bone Marrow Transplant 20:369–74, 1997

    Article  PubMed  CAS  Google Scholar 

  75. Bernard M, Dauriac C, Drenou B, et al: Long-term follow-up of allogeneic bone marrow transplantation in patients with poor prognosis non-Hodgkin’s lymphoma. Bone Marrow Transplant 23:329–33, 1999

    Article  PubMed  CAS  Google Scholar 

  76. Chopra R, Goldstone AH, Pearce R, et al: Autologous versus allogeneic bone marrow transplantation for non-Hodgkin’s lymphoma: a case-controlled analysis of the European Bone Marrow Transplant Group Registry data. J Clin Oncol 10:1690–5, 1992

    PubMed  CAS  Google Scholar 

  77. Lundberg JH, Hansen RM, Chitambar CR, et al: Allogeneic bone marrow transplantation for relapsed and refractory lymphoma using genotypically HLA-identical and alternative donors. J Clin Oncol 9:1848–59, 1991

    PubMed  CAS  Google Scholar 

  78. Mendoza E, Territo M, Schiller G, et al: Allogeneic bone marrow transplantation for Hodgkin’s and non-Hodgkin’s lymphoma. Bone Marrow Transplant 15:299–303, 1995

    PubMed  CAS  Google Scholar 

  79. Mitterbauer M, Neumeister P, Kalhs P, et al: Long-term clinical and molecular remission after allogeneic stem cell transplantation (SCT) in patients with poor prognosis non-Hodgkin’s lymphoma. Leukemia 15:635–41, 2001

    Article  PubMed  CAS  Google Scholar 

  80. Ratanatharathorn V, Uberti J, Karanes C, et al: Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with non-Hodgkin’s lymphoma. Blood 84:1050–5, 1994

    PubMed  CAS  Google Scholar 

  81. Schimmer AD, Jamal S, Messner H, et al: Allogeneic or autologous bone marrow transplantation (BMT) for non-Hodgkin’s lymphoma (NHL): results of a provincial strategy. Ontario BMT Network, Canada. Bone Marrow Transplant 26:859–64, 2000

    Article  PubMed  CAS  Google Scholar 

  82. Longo DL: The use of chemotherapy in the treatment of Hodgkin’s disease. Semin Oncol 17:716–35, 1990

    PubMed  CAS  Google Scholar 

  83. Buzaid AC, Lippman SM, Miller TP: Salvage therapy of advanced Hodgkin’s disease. Critical appraisal of curative potential. Am J Med 83:523–32, 1987

    Article  PubMed  CAS  Google Scholar 

  84. Longo DL, Duffey PL, Young RC, et al: Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin’s disease after combination chemotherapy: the low probability for cure. J Clin Oncol 10:210–8, 1992

    PubMed  CAS  Google Scholar 

  85. Nademanee A, O’Donnell MR, Snyder DS, et al: High-dose chemotherapy with or without total body irradiation followed by autologous bone marrow and/or peripheral blood stem cell transplantation for patients with relapsed and refractory Hodgkin’s disease: results in 85 patients with analysis of prognostic factors. Blood 85:1381–90, 1995

    PubMed  CAS  Google Scholar 

  86. Anderson JE, Litzow MR, Appelbaum FR, et al: Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin’s disease: the 21-year Seattle experience. J Clin Oncol 11:2342–50, 1993

    PubMed  CAS  Google Scholar 

  87. Milpied N, Vasseur B, Parquet N, et al: Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients. Ann.Oncol. 11Suppl 1:113–116, 2000

    Article  PubMed  Google Scholar 

  88. Verdonck LF, Dekker AW, Lokhorst HM, et al: Allogeneic versus autologous bone marrow transplantation for refractory and recurrent low-grade non-Hodgkin’s lymphoma. Blood 90:4201–5, 1997

    PubMed  CAS  Google Scholar 

  89. Appelbaum FR, Sullivan KM, Buckner CD, et al: Treatment of malignant lymphoma in 100 patients with chemotherapy, total body irradiation, and marrow transplantation. J Clin Oncol 5:1340–7, 1987

    PubMed  CAS  Google Scholar 

  90. Phillips GL, Wolff SN, Herzig RH, et al: Treatment of progressive Hodgkin’s disease with intensive chemoradiotherapy and autologous bone marrow transplantation. Blood 73:2086–92, 1989

    PubMed  CAS  Google Scholar 

  91. Santos GW, Tutschka PJ, Brookmeyer R, et al: Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. N.Engl.J.Med. 309:1347–1353, 1983

    Article  PubMed  CAS  Google Scholar 

  92. Tutschka PJ, Copelan EA, Klein JP: Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen. Blood 70:1382–8, 1987

    PubMed  CAS  Google Scholar 

  93. Demirer T, Weaver CH, Buckner CD, et al: High-dose cyclophosphamide, carmustine, and etoposide followed by allogeneic bone marrow transplantation in patients with lymphoid malignancies who had received prior dose-limiting radiation therapy. J Clin Oncol 13:596–602, 1995

    PubMed  CAS  Google Scholar 

  94. Przepiorka D, van Besien K, Khouri I, et al: Carmustine, etoposide, cytarabine and melphalan as a preparative regimen for allogeneic transplantation for high-risk malignant lymphoma. Ann Oncol 10:527–32, 1999

    PubMed  CAS  Google Scholar 

  95. Chopra R, McMillan AK, Linch DC, et al: The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin’s disease. A single-center eight-year study of 155 patients. Blood 81:1137–45, 1993

    PubMed  CAS  Google Scholar 

  96. Kroger N, Hofflcnecht M, Hanel M, et al: Busulfan, cyclophosphamide and etoposide as high-dose conditioning therapy in patients with malignant lymphoma and prior dose-limiting radiation therapy. Bone Marrow Transplant 21:1171–5, 1998

    Article  PubMed  CAS  Google Scholar 

  97. Thomas ED, Storb R: Technique for human marrow grafting. Blood 36:507–15, 1970

    PubMed  CAS  Google Scholar 

  98. Korbling M, Burke P, Braine H, et al: Successful engraftment of blood derived normal hemopoietic stem cells in chronic myelogenous leukemia. Exp Hematol 9:684–90, 1981

    PubMed  CAS  Google Scholar 

  99. Thomas DB: The infusion of human fetal liver cells. Stem Cells 11Suppl 1:66–71, 1993

    Article  PubMed  Google Scholar 

  100. Gluckman E, Broxmeyer HA, Auerbach AD, et al: Hematopoietic reconstitution in a patient with Fanconi’s anemia by means of umbilical-cord blood from an HLA-identical sibling. N Engl J Med 321:1174–8, 1989

    Article  PubMed  CAS  Google Scholar 

  101. Thomas E, Storb R, Clift RA, et al: Bone-marrow transplantation (first of two parts). N Engl J Med 292:832–43, 1975

    Article  PubMed  CAS  Google Scholar 

  102. Thomas ED, Storb R, Clift RA, et al: Bone-marrow transplantation (second of two parts). N Engl J Med 292:895–902, 1975

    Article  PubMed  CAS  Google Scholar 

  103. McCredie KB, Hersh EM, Freireich EJ: Cells capable of colony formation in the peripheral blood of man. Science 171:293–4, 1971

    Article  PubMed  CAS  Google Scholar 

  104. Korbling M, Huh YO, Durett A, et al: Allogeneic blood stem cell transplantation: peripheralization and yield of donor-derived primitive hematopoietic progenitor cells (CD34+ Thy-ldim) and lymphoid subsets, and possible predictors of engraftment and graft-versus-host disease. Blood 86:2842–8, 1995

    PubMed  CAS  Google Scholar 

  105. Appelbaum FR, Herzig GP, Ziegler JL, et al: Successful engraftment of cryopreserved autologous bone marrow in patients with malignant lymphoma. Blood 52:85–95, 1978

    PubMed  CAS  Google Scholar 

  106. Kessinger A, Armitage JO, Landmark JD, et al: Autologous peripheral hematopoietic stem cell transplantation restores hematopoietic function following marrow ablative therapy. Blood 71:723–7, 1988

    PubMed  CAS  Google Scholar 

  107. Bensinger WI, Martin PJ, Storer B, et al: Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med 344:175–81, 2001

    Article  PubMed  CAS  Google Scholar 

  108. Vigorito AC, Azevedo WM, Marques JF, et al: A randomised, prospective comparison of allogeneic bone marrow and peripheral blood progenitor cell transplantation in the treatment of haematological malignancies. Bone Marrow Transplant 22:1145–51, 1998

    Article  PubMed  CAS  Google Scholar 

  109. Blaise D, Kuentz M, Fortanier C, et al: Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia: a report from the Societe Francaise de Greffe de Moelle. J Clin Oncol 18:537–46, 2000

    PubMed  CAS  Google Scholar 

  110. Ringden O, Horowitz MM, Sondel P, et al: Methotrexate, cyclosporine, or both to prevent graft-versus-host disease after HLA-identical sibling bone marrow transplants for early leukemia? Blood 81:1094–101, 1993

    PubMed  CAS  Google Scholar 

  111. Heldal D, Tjonnfjord G, Brinch L, et al: A randomised study of allogeneic transplantation with stem cells from blood or bone marrow. Bone Marrow Transplant 25:1129–36, 2000

    Article  PubMed  CAS  Google Scholar 

  112. Powles R, Mehta J, Kulkarni S, et al: Allogeneic blood and bone-marrow stem-cell transplantation in haematological malignant diseases: a randomised trial. Lancet 355:1231–7, 2000

    Article  PubMed  CAS  Google Scholar 

  113. Champlin RE, Schmitz N, Horowitz MM, et al: Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. IBMTR Histocompatibility and Stem Cell Sources Working Committee and the European Group for Blood and Marrow Transplantation (EBMT). Blood 95:3702–9, 2000

    PubMed  CAS  Google Scholar 

  114. Cavallaro AM, Lilleby K, Majolino I, et al: Three to six year follow-up of normal donors who received recombinant human granulocyte colony-stimulating factor. Bone Marrow Transplant 25:85–9, 2000

    Article  PubMed  CAS  Google Scholar 

  115. Deeg HJ, Storb R, Thomas ED, et al: Cyclosporine as prophylaxis for graft-versus-host disease: a randomized study in patients undergoing marrow transplantation for acute nonlymphoblastic leukemia. Blood 65:1325–34, 1985

    PubMed  CAS  Google Scholar 

  116. Storb R, Deeg HJ, Whitehead J, et al: Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 314:729–35, 1986

    Article  PubMed  CAS  Google Scholar 

  117. Ratanatharathom V, Nash RA, Przepiorka D, et al: Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood 92:2303–14, 1998

    Google Scholar 

  118. Reisner Y, Kapoor N, O’Reilly RJ, et al: Allogeneic bone marrow transplantation using stem cells fractionated by lectins: VI, in vitro analysis of human and monkey bone marrow cells fractionated by sheep red blood cells and soybean agglutinin. Lancet 2:1320–4, 1980

    Article  PubMed  CAS  Google Scholar 

  119. Filipovich AH, McGlave PB, Ramsay NK, et al: Pretreatment of donor bone marrow with monoclonal antibody OKT3 for prevention of acute graft-versus-host disease in allogeneic histocompatible bone-marrow transplantation. Lancet 1:1266–9, 1982

    Article  PubMed  CAS  Google Scholar 

  120. Waldmann H, Polliak A, Hale G, et al: Elimination of graft-versus-host disease by in-vitro depletion of alloreactive lymphocytes with a monoclonal rat anti-human lymphocyte antibody (CAMPATH-1). Lancet 2:483–6, 1984

    Article  PubMed  CAS  Google Scholar 

  121. Heit W, Bunjes D, Wiesneth M, et al: Ex vivo T-cell depletion with the monoclonal antibody Campath-1 plus human complement effectively prevents acute graft-versus-host disease in allogeneic bone marrow transplantation. Br J Haematol 64:479–86, 1986

    PubMed  CAS  Google Scholar 

  122. Cull GM, Haynes AP, Byrne JL, et al: Preliminary experience of allogeneic stem cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH conditioning: an effective regimen with low procedure-related toxicity. Br.J.Haematol. 108:754–760, 2000

    Article  PubMed  CAS  Google Scholar 

  123. Wagner JE, Donnenberg AD, Noga SJ, et al: Lymphocyte depletion of donor bone marrow by counterflow centrifugal elutriation: results of a phase I clinical trial. Blood 72:1168–76, 1988

    PubMed  CAS  Google Scholar 

  124. Noga SJ, Vogelsang GB, Seber A, et al: CD34+ stem cell augmentation of allogeneic, elutriated marrow grafts improves engraftment but cyclosporine A is still required to reduce GVHD and morbidity. Transplant Proc 29:728–32, 1997

    Article  PubMed  CAS  Google Scholar 

  125. Soiffer RJ, Freedman AS, Neuberg D, et al: CD6+ T cell-depleted allogeneic bone marrow transplantation for non-Hodgkin’s lymphoma. Bone Marrow Transplant 21:1177–81, 1998

    Article  PubMed  CAS  Google Scholar 

  126. Maraninchi D, Gluckman E, Blaise D, et al: Impact of T-cell depletion on outcome of allogeneic bone-marrow transplantation for standard-risk leukaemias. Lancet 2:175–8, 1987

    Article  PubMed  CAS  Google Scholar 

  127. Nigam A, Yacavone RF, Zahurak ML, et al: Immunomodulatory properties of antineoplastic drugs administered in conjunction with GM-CSF-secreting cancer cell vaccines. Int J Oncol 12:161–70, 1998

    PubMed  CAS  Google Scholar 

  128. Mackinnon S, Papadopoulos EB, Carabasi MH, et al: Adoptive immunotherapy evaluating escalating doses of donor leukocytes relapse of chronic myeloid leukemia after bone marrow transplantation: Separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 86:1261–1268, 1995

    PubMed  CAS  Google Scholar 

  129. Soiffer RJ, Alyea EP, Hochberg E, et al: Randomized trial of CD8+ T-cell depletion in the prevention of graft-versus-host disease associated with donor lymphocyte infusion. Biol Blood Marrow Transplant 8:625–32, 2002

    Article  PubMed  Google Scholar 

  130. Kim YM, Sachs T, Asavaroengchai W, et al: Graft-versus-host disease can be separated from graft-versus-lymphoma effects by control of lymphocyte trafficking with FTY720. J Clin Invest 111:659–69, 2003

    PubMed  CAS  Google Scholar 

  131. Slavin S, Nagler A, Naparstek E, et al: Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 91:756–763, 1998

    PubMed  CAS  Google Scholar 

  132. Khouri IF, Keating M, Korbling M, et al: Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 16:2817–24, 1998

    PubMed  CAS  Google Scholar 

  133. Craddock C, Bardy P, Kreiter S, et al: Short Report: Engraftment of T-cell-depleted allogeneic haematopoietic stem cells using a reduced intensity conditioning regimen. Br J Haematol 111:797–800, 2000

    Article  PubMed  CAS  Google Scholar 

  134. Corradini P, Tarella C, Olivieri A, et al: Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies. Blood 99:75–82, 2002

    Article  PubMed  CAS  Google Scholar 

  135. Champlin R, Khouri I, Shimoni A, et al: Harnessing graft-versus-malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy. Br J Haematol 111:18–29, 2000

    Article  PubMed  CAS  Google Scholar 

  136. Bornhauser M, Thiede C, Platzbecker U, et al: Dose-reduced conditioning and allogeneic hematopoietic stem cell transplantation from unrelated donors in 42 patients. Clin Cancer Res 7:2254–62, 2001

    PubMed  CAS  Google Scholar 

  137. Khouri IF, Saliba RM, Giralt SA, et al: Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood 98:3595–9, 2001

    Article  PubMed  CAS  Google Scholar 

  138. Robinson SP, Goldstone AH, Mackinnon S, et al: Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood 100:4310–6, 2002

    Article  PubMed  CAS  Google Scholar 

  139. Perez-Simon JA, Kottaridis PD, Martino R, et al: Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders. Blood 100:3121–7, 2002

    Article  PubMed  CAS  Google Scholar 

  140. Branson K, Chopra R, Kottaridis PD, et al: Role of nonmyeloablative allogeneic stem-cell transplantation after failure of autologous transplantation in patients with lymphoproliferative malignancies. J Clin Oncol 20:4022–31, 2002

    Article  PubMed  Google Scholar 

  141. Dreger P, Brand R, Hansz J, et al: Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning. Leukemia 17:841–8, 2003

    Article  PubMed  CAS  Google Scholar 

  142. Carella AM, Cavaliere M, Lerma E, et al: Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin’s disease and non-Hodgkin’s lymphoma. J Clin Oncol 18:3918–24, 2000

    PubMed  CAS  Google Scholar 

  143. Mohty M, Fegueux N, Exbrayat C, et al: Reduced intensity conditioning: enhanced graft-versus-tumor effect following dose-reduced conditioning and allogeneic transplantation for refractory lymphoid malignancies after high-dose therapy. Bone Marrow Transplant 28:335–9, 2001

    Article  PubMed  CAS  Google Scholar 

  144. Weissinger F, Sandmaier BM, Maloney DG, et al: Decreased transfusion requirements for patients receiving nonmyeloablative compared with conventional peripheral blood stem cell transplants from HLA-identical siblings. Blood 98:3584–8, 2001

    Article  PubMed  CAS  Google Scholar 

  145. Nagler A, Slavin S, Varadi G, et al: Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma. Bone Marrow Transplant 25:1021–8, 2000

    Article  PubMed  CAS  Google Scholar 

  146. Raiola AM, Van Lint MT, Lamparelli T, et al: Reduced intensity thiotepa-cyclophosphamide conditioning for allogeneic haemopoietic stem cell transplants (HSCT) in patients up to 60 years of age. Br J Haematol 109:716–21, 2000

    Article  PubMed  CAS  Google Scholar 

  147. Alessandrino EP, Bernasconi P, Colombo AA, et al: Thiotepa and fludarabine (TT-FLUDA) as conditioning regimen in poor candidates for conventional allogeneic hemopoietic stem cell transplant. Ann Hematol 80:521–4, 2001

    Article  PubMed  CAS  Google Scholar 

  148. Giralt S, Thall PF, Khouri I, et al: Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood 97:631–7, 2001

    Article  PubMed  CAS  Google Scholar 

  149. Wasch R, Reisser S, Hahn J, et al: Rapid achievement of complete donor chimerism and low regimen-related toxicity after reduced conditioning with fludarabine, carmustine, melphalan and allogeneic transplantation. Bone Marrow Transplant 26:243–50, 2000

    Article  PubMed  CAS  Google Scholar 

  150. Bainton RD, Byrne JL, Davy BJ, et al: CMV infection following nonmyeloablative allogeneic stem cell transplantation using Campath. Blood 100:3843–4, 2002

    Article  PubMed  Google Scholar 

  151. Kottaridis PD, Milligan DW, Chopra R, et al: In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood 96:2419–25, 2000

    PubMed  CAS  Google Scholar 

  152. Chakrabarti S, Mackinnon S, Chopra R, et al: High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. Blood 99:4357–63, 2002

    Article  PubMed  CAS  Google Scholar 

  153. Chakraverty R, Peggs K, Chopra R, et al: Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. Blood 99:1071–8, 2002

    Article  PubMed  CAS  Google Scholar 

  154. Niederwieser D, Maris M, Shizuru JA, et al: Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood 101:1620–9, 2003

    Article  PubMed  CAS  Google Scholar 

  155. Sykes M, Preffer F, McAfee S, et al: Mixed lymphohaemopoietic chimerism and graft-versus-lymphoma effects after non-myeloablative therapy and HLA-mismatched bone-marrow transplantation. Lancet 353:1755–9, 1999

    Article  PubMed  CAS  Google Scholar 

  156. Maloney DG, Molina AJ, Sahebi F, et al: Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood, 2003

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Bunting-Blaustein Cancer Research Building, 1650 Orleans Street/Room 388, Baltimore, MD, 21231-1000

    Ian W. Flinn M.D., Ph.D. & Jesus G. Berdeja

Authors
  1. Ian W. Flinn M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jesus G. Berdeja
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Center for Lymphoma and Myeloma, Weill Medical College of Cornell University The New York Presbyterian Hospital, New York, New York

    John P. Leonard MD  & Morton Coleman MD  & 

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Flinn, I.W., Berdeja, J.G. (2006). Blood and Bone Marrow Transplantation for Patients with Hodgkin’s and Non-Hodgkin’s Lymphoma. In: Leonard, J.P., Coleman, M. (eds) Hodgkin’s and Non-Hodgkin’s Lymphoma. Cancer Treatment and Research, vol 131. Springer, Boston, MA. https://doi.org/10.1007/978-0-387-29346-2_8

Download citation

  • DOI: https://doi.org/10.1007/978-0-387-29346-2_8

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-0-387-29345-5

  • Online ISBN: 978-0-387-29346-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation